Clinical trials: Antibody Mediated
Antibody Mediated Rejection
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor kidney transplant requiring desensitization…
- Trial name
- NCT01399593
- Testing
- Eculizumab
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Antibody-mediated Rejection, Humoral Rejection
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
This is an open-label analysis that will compare eculizumab versus Plasmapheresis (PP) and Immunoglobulin (IVIg) for the treatment of antibody-mediated rejection (AMR) in renal transplant recipients.
- Trial name
- NCT01895127
- Testing
- Eculizumab, Immunoglobulin, Plasmapheresis
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brigham and Women's Hospital
Cardiac Allograft Vasculopathy, Antibody Mediated Rejection
Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation
Coronary allograft vasculopathy (CAV) is the leading cause of late graft failure and second leading cause of late mortality after heart transplantation.
- Trial name
- NCT01848301
- Testing
- Optical Coherence Tomography, Acetylcholine, Brachial Artery Flow Mediated Dilation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gladwin, Mark, MD
Immunity; Defect Due to Antibody or Cell Mediated Immune Defect
Cytokine Production and Immunity to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine
After immunization, particularly in older persons, some people are protected from disease by a vaccine and others are not. The investigators believe that this variable response may be due to overproduction of molecules that…
- Trial name
- NCT01288014
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Columbia University
Late Rejection of Renal Transplant, Antibody-mediated Rejection
Bortezomib in Late Antibody-mediated Kidney Transplant Rejection
Late antibody-mediated rejection (AMR) after kidney transplantation is defined as a separate rejection entity. So far, no appropriate treatment has been established for this rejection type.
- Trial name
- BORTEJECT (NCT01873157)
- Testing
- Bortezomib
- Where
- Austria
- Volunteers
- 44 people
- Sponsor
- Medical University of Vienna
Antibody-mediated Rejection, Autoimmune Reaction Mediated by Immune Complex
Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange
Therapeutic plasma exchange (TPE) is an established treatment modality for the acute removal of pathophysiological relevant mediators in various diseases.
- Trial name
- NCT02533596
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Hannover Medical School